Payment overview · 2025
General Payments
$979.09
55 reported records · 15 companies
Healthcare provider profile · identity verified
Mohammad Anisur Rahman, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CHARLOTTE, NC · NPI 1861465288
Verified facts
What the public records show
CMS Open Payments records show Mohammad Anisur Rahman, MD received $979.09 in general payments during 2025 across 55 reported records.
Novo Nordisk Inc accounted for 18.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Paxlovid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $181.80 | 18.6% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $161.76 | 16.5% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $145.00 | 14.8% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $137.66 | 14.1% | 7 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $65.78 | 6.7% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $61.55 | 6.3% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $44.03 | 4.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $34.87 | 3.6% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $28.57 | 2.9% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$21.67 | 2.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.00 | 2.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.78 | 2.1% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $20.18 | 2.1% | 1 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $19.88 | 2.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.56 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $979.09 | 55 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $137.12 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $137.12 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $124.61 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $90.27 | 8 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $78.94 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $78.90 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $61.55 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $46.24 | 6 | 2025 |
Source payment records
|
|||||
| AMS 700 Normalized: ams 700 |
Device | Boston Scientific Corporation | $44.03 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $41.67 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $41.67 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $41.67 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $41.38 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $40.28 | 3 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $29.82 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $28.57 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $27.50 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $25.78 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $25.78 | 2 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $24.40 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $21.67 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $19.88 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $13.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 57 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 80 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 24 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
42 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
57 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
80 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
57 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
24 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 442 | 132 |
| Amlodipine Besylate | Amlodipine Besylate | 300 | 94 |
| Losartan Potassium | Losartan Potassium | 280 | 87 |
| Levothyroxine Sodium | Levothyroxine Sodium | 238 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 229 | 68 |
| Omeprazole | Omeprazole | 210 | 64 |
| Prednisone | Prednisone | 205 | 116 |
| Metformin Hcl Er | Metformin Hcl | 195 | 60 |
| Clonazepam | Clonazepam | 182 | 37 |
| Trazodone Hcl | Trazodone Hcl | 174 | 52 |
| Torsemide | Torsemide | 172 | 56 |
| Zolpidem Tartrate | Zolpidem Tartrate | 165 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 161 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 154 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 151 | 44 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 151 | 63 |
| Gabapentin | Gabapentin | 149 | 42 |
| Simvastatin | Simvastatin | 142 | 37 |
| Lisinopril | Lisinopril | 141 | 43 |
| Diclofenac Sodium | Diclofenac Sodium | 136 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 130 | 52 |
| Carvedilol | Carvedilol | 105 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 101 | 28 |
| Allopurinol | Allopurinol | 96 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 94 | 28 |
| Tramadol Hcl | Tramadol Hcl | 93 | 36 |
| Doxycycline Hyclate | Doxycycline Hyclate | 92 | 67 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 85 | 68 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 81 | 38 |
| Glipizide Er | Glipizide | 80 | 21 |
| Ozempic | Semaglutide | 80 | 19 |
| Celecoxib | Celecoxib | 78 | 20 |
| Meloxicam | Meloxicam | 75 | 25 |
| Montelukast Sodium | Montelukast Sodium | 73 | 25 |
| Potassium Chloride | Potassium Chloride | 72 | 24 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 72 | 59 |
| Tizanidine Hcl | Tizanidine Hcl | 70 | 22 |
| Irbesartan | Irbesartan | 69 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 19 |
| Alprazolam | Alprazolam | 67 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 67 | 21 |
| Chlorthalidone | Chlorthalidone | 63 | 16 |
| Bupropion Xl | Bupropion Hcl | 61 | 18 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 60 | 17 |
| Glimepiride | Glimepiride | 58 | 18 |
| Eliquis | Apixaban | 57 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 26 |
| Methocarbamol | Methocarbamol | 53 | 24 |
| Buspirone Hcl | Buspirone Hcl | 47 | 18 |
| Lactulose | Lactulose | 47 | 25 |
| Cephalexin | Cephalexin | 46 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | 13 |
| Azithromycin | Azithromycin | 44 | 40 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 42 | 13 |
| Synthroid | Levothyroxine Sodium | 42 | 13 |
| Fenofibrate | Fenofibrate | 41 | 12 |
| Sertraline Hcl | Sertraline Hcl | 41 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 13 |
| Ondansetron Odt | Ondansetron | 39 | 19 |
| Ezetimibe | Ezetimibe | 38 | 11 |
| Metformin Hcl | Metformin Hcl | 38 | suppressed |
| Furosemide | Furosemide | 37 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 36 | 13 |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Lorazepam | Lorazepam | 35 | suppressed |
| Bumetanide | Bumetanide | 33 | suppressed |
| Diazepam | Diazepam | 32 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 31 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 29 | suppressed |
| Pregabalin | Pregabalin | 29 | 11 |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 25 |
| Famotidine | Famotidine | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 15 |
| Acyclovir | Acyclovir | 25 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 13 |
| Temazepam | Temazepam | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | 13 |
| Baclofen | Baclofen | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | 13 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 16 |
| Prazosin Hcl | Prazosin Hcl | 19 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 18 | 11 |
| Ketoconazole | Ketoconazole | 17 | 12 |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | 13 |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Tivicay | Dolutegravir Sodium | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Darunavir | Darunavir | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $979.09 · 55 records | Novo Nordisk Inc | ABRYSVO, ACCRUFER, AIRSUPRA, AMS 700, Barostim Neo System, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ELIQUIS, ETERNA, EVENITY, FREESTYLE LIBRE 3, GARDASIL 9, INCEPTIV, JARDIANCE, KRYSTEXXA, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, UBRELVY, VRAYLAR, Wegovy, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error